You are here: Industry Insights > Beam Therapeutics

News List

Oxford Biomedica and Beam Therapeutics sign CAR-T deal pharmatimes
August 04, 2020
UK-based Oxford Biomedica has signed a new development, manufacture and license agreement with Beam Therapeutics for next-generation CAR-T therapeutics.
Beam Therapeutics licenses Bio Palette’s base editing technologies pharmaceutical-technology
June 05, 2019
Bio Palette has signed a cross-license agreement granting Beam Therapeutics a licence for its intellectual property (IP) to develop new therapeutics.
Beam Therapeutics, Bio Palette to develop microbiome-related therapeutics in Asia biospectrumasia
June 03, 2019
Bio Palette licenses base editing intellectual property to Beam Therapeutics for use in human therapeutics
Beam Therapeutics raises $135m to advance CRISPR technologies pharmaceutical-technology
March 08, 2019
US-based precision genetic medicines developer Beam Therapeutics has raised $135m in a series B funding round to drive the development of next-generation CRISPR technologies.
Beam Therapeutics raises $135m to advance CRISPR technologies pharmaceutical-technology
March 08, 2019
US-based precision genetic medicines developer Beam Therapeutics has raised $135m in a series B funding round to drive the development of next-generation CRISPR technologies.